The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies

Background: Among the several therapeutic options assessed for the treatment of coronavirus disease 2019 (COVID-19), tocilizumab (TCZ), an antagonist of the interleukine-6 receptor, has emerged as a promising therapeutic choice, especially for the severe form of the disease. Proper synthesis of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Maraolo, Alberto Enrico, Crispo, Anna, Piezzo, Michela, Di Gennaro, Piergiacomo, Vitale, Maria Grazia, Mallardo, Domenico, Ametrano, Luigi, Celentano, Egidio, Cuomo, Arturo, Ascierto, Paolo A., Cascella, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584705/
https://www.ncbi.nlm.nih.gov/pubmed/34768455
http://dx.doi.org/10.3390/jcm10214935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584705/
https://www.ncbi.nlm.nih.gov/pubmed/34768455
http://dx.doi.org/10.3390/jcm10214935

Ejemplares similares